| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | AVBP | Common Stock | 219K | Jan 25, 2024 | Held by ArriMed BioPharma, LLC | F1, F2 | |||||
| holding | AVBP | Common Stock | 394K | Jan 25, 2024 | Held by The MAKS Yao Trust | F1, F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | AVBP | Stock Option (right to buy) | Jan 25, 2024 | Common Stock | 105K | $2.28 | Direct | F4, F5 | ||||||
| holding | AVBP | Stock Option (right to buy) | Jan 25, 2024 | Common Stock | 104K | $2.28 | Direct | F5, F6 | ||||||
| holding | AVBP | Stock Option (right to buy) | Jan 25, 2024 | Common Stock | 141K | $2.28 | Direct | F5, F6 | ||||||
| holding | AVBP | Stock Option (right to buy) | Jan 25, 2024 | Common Stock | 141K | $3.65 | Direct | F5, F7 | ||||||
| holding | AVBP | Stock Option (right to buy) | Jan 25, 2024 | Common Stock | 265K | $7.76 | Direct | F5, F8 |
| Id | Content |
|---|---|
| F1 | Reflects the 15.21-for-1 reverse stock split of the Issuer's common stock effected on January 23, 2024 in connection with the Issuer's initial public offering. |
| F2 | Dr. Yao has sole voting power and investment control over the common stock held by ArriMed BioPharma, LLC. Dr. Yao disclaims beneficial ownership of the securities held by the trust except to the extent of his pecuniary interest therein, if any. |
| F3 | Robin LaChapelle, Chief Operating Officer of the Issuer, is the Trustee of The MAKS Yao Trust and may be deemed to have shared voting and investment power over the shares held by The MAKS Yao Trust. Members of the Reporting Person's immediate family are the beneficiaries of such trust. The Reporting Person disclaims beneficial ownership of the securities held by The MAKS Yao Trust except to the extent of his pecuniary interest therein, if any. |
| F4 | The shares underlying this option vested as to 25% on September 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. |
| F5 | Reflects the 15.21-for-1 reverse stock split of the Issuer's common stock effected on January 23, 2024 in connection with the Issuer's initial public offering, pursuant to which (i) the number of shares of common stock underlying the option was divided by 15.21 and (ii) the exercise price of the option was multiplied by 15.21. |
| F6 | The shares underlying this option vested as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. |
| F7 | The shares underlying this option vest as to 25% on February 1, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. |
| F8 | The shares underlying this option vest as to 25% on January 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. |
Exhibit 24.1 - Power of Attorney